May autophagy be a novel biomarker and antitumor target in colorectal cancer?

Biomark Med. 2016 Oct;10(10):1081-1094. doi: 10.2217/bmm-2016-0083. Epub 2016 Sep 14.

Abstract

Autophagy is a catabolic process associated with intracellular self-digestion of damaged organelles or redundant proteins enabling maintenance of cell homeostasis. It is accepted that impaired autophagy is closely linked to cancer development and has been extensively studied in a variety of malignancies including colorectal cancer (CRC) to elucidate its influence on carcinogenesis, metastasis and antitumor therapy response. CRC remains a great epidemiological problem because of poor 5-year survival and treatment resistance. Many studies concerning autophagy in CRC gave inconsistent and contradictory results, illustrating a multifaceted nature of this process. In this review, we focus on current knowledge of autophagy in CRC development to determinate its role as a potential prognostic and predictive biomarker as well as target in antitumor therapy.

Keywords: ATG; BECN1; LC3; autophagosome; autophagy; colorectal cancer; gene expression; immunohistochemistry; protein expression.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Autophagy*
  • Autophagy-Related Protein 5 / genetics
  • Autophagy-Related Protein 5 / metabolism
  • Beclin-1 / genetics
  • Beclin-1 / metabolism
  • Biomarkers, Tumor / genetics
  • Biomarkers, Tumor / metabolism*
  • Colorectal Neoplasms / drug therapy
  • Colorectal Neoplasms / mortality
  • Colorectal Neoplasms / pathology*
  • Humans
  • Microsatellite Repeats / genetics
  • Microtubule-Associated Proteins / genetics
  • Microtubule-Associated Proteins / metabolism
  • Prognosis

Substances

  • Antineoplastic Agents
  • Autophagy-Related Protein 5
  • BECN1 protein, human
  • Beclin-1
  • Biomarkers, Tumor
  • MAP1LC3A protein, human
  • Microtubule-Associated Proteins